Yes, Aducanumab may very well have had mild efficacy in the high dose group. But clearly the two newer drugs appear superior. Especially, when considering the s

Yes, Aducanumab may very well have had mild efficacy in the high dose group. But clearly the two newer drugs appear superior. Especially, when considering the side-effect profile. It will be exciting to see how efficacious these amyloid-beta antibodies can become and there is also clearly a small mystery (or at least a lack of consensus) in why the newer drugs show efficacy and the previous ones all failed.